<?xml version="1.0" encoding="UTF-8"?>
<p>Though, a focus on the ACE2 activity accompanying COVID-19 may be considered commonplace, it is arguably one of the significant direct/indirect targets for therapeutics in COVID-19. ACE2 physiology is important in hypertension, cardiac, kidney, and lung physiology (
 <xref rid="B113" ref-type="bibr">Tikellis and Thomas, 2012</xref>). The apparent relevance of ACE2 physiology in COVID-19 has come in two ways, both supporting immense clinical focus on its modulation: 1
 <bold>)</bold> as a receptor for SARS COV2 (
 <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link> identifiers: 
 <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/NCT04335136" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04335136</ext-link>) and 2
 <bold>)</bold> as an enzyme for the generation of ANG 1â€“7 (
 <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link> identifiers: 
 <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/NCT04311177" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04311177</ext-link>, 
 <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/NCT04312009" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04312009</ext-link>, 
 <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/NCT04338009" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04338009</ext-link>, 
 <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/NCT04338009" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04338009</ext-link>, 
 <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/NCT04394117" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04394117</ext-link>, and 
 <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/NCT04394117" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04394117</ext-link>) (
 <xref rid="B8" ref-type="bibr">Bhalla et al., 2020</xref>). The unfortunate neglect of ACE2 therapeutic potential (and lessons learned) following SARS-CoV outbreak strongly necessitated and still advocates for the recent efforts to develop ACE2-centered therapeutics for the current SARS COV2 (
 <xref rid="B8" ref-type="bibr">Bhalla et al., 2020</xref>). Thus, efforts (till date) to find an ACE2-centered therapeutic are re-emerging with a steep focus after its rediscovery as a receptor for SARS COV 2 (
 <xref rid="B51" ref-type="bibr">Hoffmann et al., 2020</xref>).
</p>
